NW
CORT icon

NewEdge Wealth’s Corcept Therapeutics CORT Stock Holding History

NewEdge Wealth’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.03M Buy
34,890
+7,003
+25% +$423K 0.03% 350
2026
Q1 		$1.12M Buy
27,887
+19,546
+234% +$731K 0.01% 590
2025
Q4 		$290K Buy
8,341
+1,126
+16% +$88.4K ﹤0.01% 1033
2025
Q3 		$553K Buy
7,215
+1,267
+21% +$91.7K 0.01% 718
2025
Q2 		$425K Sell
5,948
-8,959
-60% -$650K 0.01% 748
2025
Q1 		$1.7M Buy
14,907
+2,387
+19% +$145K 0.03% 382
2024
Q4 		$631K Buy
12,520
+7,563
+153% +$396K 0.01% 590
2024
Q3 		$229K Buy
+4,957
New +$176K ﹤0.01% 800

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

NewEdge Wealth's CORT Position: Q2 2026 in Review

NewEdge Wealth increased its Corcept Therapeutics (CORT) stake by 25% in Q2 2026, buying an estimated $423K and bringing the position to 34,890 shares worth $3.03M. The position accounts for 0.03% of the portfolio, ranked #350.

NewEdge Wealth first reported a position in CORT in Q3 2024 and has held it in 8 quarters since. 423 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • NewEdge Wealth held 34,890 shares of Corcept Therapeutics worth $3.03M as of Q2 2026.
  • NewEdge Wealth bought 7,003 Corcept Therapeutics shares in Q2 2026, an estimated $423K.
  • Corcept Therapeutics made up 0.03% of NewEdge Wealth's portfolio in Q2 2026, its #350 holding.
  • NewEdge Wealth first reported a position in Corcept Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • 423 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on NewEdge Wealth's 13F filing for Q2 2026, filed 10 Aug 2026.